68Ga-DOTATATE for Tumor Localization in Tumor-Induced Osteomalacia | Zendy

Diala ElMaouche | Zendy; Samira M. Sadowski | Zendy; Georgios Z. Papadakis | Zendy; Lori C. Guthrie | Zendy; Candice CottleDelisle | Zendy; Roxanne Merkel | Zendy; Corina Millo | Zendy; Clara C. Chen | Zendy; Electron Kebebew | Zendy; Michael T. Collins | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

⁶⁸Ga-DOTATATE for Tumor Localization in Tumor-Induced Osteomalacia

Author(s) -

Diala ElMaouche,

Samira M. Sadowski,

Georgios Z. Papadakis,

Lori C. Guthrie,

Candice CottleDelisle,

Roxanne Merkel,

Corina Millo,

Clara C. Chen,

Electron Kebebew,

Michael T. Collins

Publication year - 2016

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2016-2052

Subject(s) - medicine , somatostatin receptor , nuclear medicine , positron emission tomography , positron emission tomography computed tomography , osteomalacia , radiology , somatostatin , pathology , osteoporosis

Phosphaturic mesenchymal tumors (PMTs) are small, typically difficult to localize, and express somatostatin receptors. Recent work suggests imaging studies using 68 Gallium ( 68 Ga)-conjugated somatostatin peptide analogues, such as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)TATE, which enables somatostatin receptor imaging with positron emission tomography (PET), may be useful at identifying these tumors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research